Form 4: Alaunos Therapeutics Director Acquires Stock Options

Holger Weis, a director of Alaunos Therapeutics, acquired stock options on June 6, 2024, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that Holger Weis, a director at Alaunos Therapeutics, acquired employee stock options on June 6, 2024.
• Weis acquired options to purchase 19,200 shares at an exercise price of $1.03, with vesting occurring monthly from June 6, 2024, until the 2025 annual general meeting.
• Additionally, Weis acquired fully vested options for 4,524 shares at an exercise price of $1.03.
• The expiration date for both sets of options is June 5, 2034.
• Following the transaction, Weis beneficially owns 19,200 and 4,524 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing indicating a director's acquisition of stock options. It doesn't inherently suggest positive or negative implications for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a company (such as directors or officers) buy or sell the company's securities. This filing indicates changes in beneficial ownership.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Form 4, Alaunos Therapeutics, Stock Options, Director, TCRT, Beneficial Ownership, Holger Weis